Amgen Announces Positive Phase 3 Results for Sjögren’s Drug

1 min read

The results came from the OASIZ-301 study of dazodalibep. Amgen plans to present the full findings at ACR Convergence 2026.

By John Kim

Published Nov 11, 2026, 11:58 PM EST

Amgen announced positive Phase 3 results Nov. 11 for dazodalibep, a therapy for Sjögren’s disease. The findings came from the OASIZ-301 study.

Amgen plans to present the full results at ACR Convergence 2026.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.